# US 6,730,696 B1 · Phospholipid derivatives of non-steroidal anti-inflammatory drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,696 B1
- Document ID: US6730696B1
- Status: Granted
- Kind: B1
- Application number: 09/856,009
- Filed: 2001-05-16
- Granted: 2004-05-04
- Earliest claimed: 1998-11-19
- Assignees: D-Pharm Ltd.
- Inventors: Alexander Kozak; Israel Shapiro
- Web page: https://patentgrep.com/patent/US6730696B1

## CPC

- C07F 9/106: {Adducts, complexes, salts of phosphatides}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 11/06: Antiasthmatics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07F 9/10: Phosphatides, e.g. lecithin
- C07F 9/5728: {condensed with carbocyclic rings or carbocyclic ring systems}
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are compounds having non-steroidal anti-inflammatory drugs (NSAIDS) covalently linked to a phospholipid moiety via a bridging group. Also disclosed are a process for the synthesis of the compounds, pharmaceutical compositions comprising the compounds and the use thereof for the treatment of diseases and disorders related to inflammatory conditions, such as the treatment of ischemia.

## Claims

### Claim 1

A compound of the general formula I
or a pharmaceutically acceptable salt thereof, wherein:
R1 is a saturated unsubstituted hydrocarbon chain having from 2 to 30 carbon atoms;
R2 is a phospholipid head group selected from the group consisting of choline, ethanolamine, inositol and serine;
D is indomethacin, wherein D is attached through a functional group to a bridging group, —C(O)—Z—X—, wherein Z is a saturated hydrocarbon chain having from 2 to 15 carbon atoms, and X is selected from amino, and thio groups.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein the conjugated residue of the nonsteroidal ant-inflammatory drug is pharmacologically inactive.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein an ester bond at position sn-2 of the phospholipid of the general formula I is cleaveable by a lipase.

### Claim 4 (depends on 3)

The compound according to claim 3, wherein said lipase is a phospholipase.

### Claim 5 (depends on 4)

The compound according to claim 4, wherein said phospholipase is phospholipase A2 (PLA2).

### Claim 6 (depends on 1)

The compound according to claim 1, wherein R1 is an hydrocarbon chain having from 10 to 20 carbon atoms.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein R1 is an hydrocarbon chain having 15 or 17 carbon atoms.

### Claim 8 (depends on 1)

The compound according to claim 1 selected from the group consisting of:
1-Stearoyl-2-{3-[2-(2,6-dichloroanilino)phenylacetamido]propanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{4-[2-(2,6-dichloroanilino)phenylacetamido]butanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{5-[2-(2,6-dichloroanilino)phenylacetamido]valeroyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{6-[2-(2,6-dichloroanilino)phenylacetamido]hexanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{8-[2-(2,6-dichloroanilino)phenylacetamido]octanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{12-[2-(2,6-dichloroanilino)phenylacetamido]dodecanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{3-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]propanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{4-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]butanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{5-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]valeroyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]hexanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{8-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]octanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{3-[α-methyl-4-(2-methylpropyl)benzeneacetamido]propanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{6-[α-methyl-4-(2-methylpropyl)benzeneacetamido]hexanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{3-[(S)-6-methoxy-α-methyl-2-naphthaleneacetamido]propanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{4-[(S)-6-methoxy-α-methyl-2-naphtaleneacetamido]butanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{6-[(S)-6-methoxy-α-methyl-2-naphthaleneacetamido]hexanoyl}-sn-glycero-3-phosphocholine, and
1-Stearoyl-2-{4-[2-(6-methoxynaphtyl)acetamido]butanoyl}-sn-glycero-3-phosphocholine.

### Claim 9

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, a compound of the general formula I
or a pharmaceutically acceptable salt thereof, wherein:
R1 is a saturated unsubstituted hydrocarbon chain having from 2 to 30 carbon atoms;
R2 is a phospholipid head group selected from the group consisting of choline, ethanolamine, inositol and serine;
D is indomethacin, wherein D is attached through a functional group to a bridging group, —C(O)—Z—X—, wherein Z is a saturated hydrocarbon chain having from 3 to 15 carbon atoms, and X is selected from amino and thio.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9, wherein —C(O)—Z—X—D is an inactive derivative of D.

### Claim 11 (depends on 9)

The pharmaceutical composition according to claim 9, wherein an ester bond at position sn-2 of the phospholipid of the general formula I is cleaveable by a lipase.

### Claim 12 (depends on 11)

The pharmaceutical composition according to claim 11, wherein said lipase is a phospholipase.

### Claim 13 (depends on 12)

The pharmaceutical composition according to claim 12, wherein said phospholipase is phospholipase A2 (PLA2).

### Claim 14 (depends on 9)

The pharmaceutical composition according to claim 9, wherein R1 is an hydrocarbon chain having from 10 to 20 carbon atoms.

### Claim 15 (depends on 9)

The pharmaceutical composition according to claim 9, wherein R1 is an hydrocarbon chain having 15 or 17 carbon atoms.

### Claim 16 (depends on 9)

The pharmaceutical composition according to claim 9, wherein said compound of the general formula I is selected from the group consisting of:
1-Stearoyl-2-{3-[2-(2,6-dichloroanilino)phenylacetamido]propanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{4-[2-(2,6-dichloroanilino)phenylacetamido]butanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{5-[2-(2,6-dichloroanilino)phenylacetamido]valeroyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{6-[2-(2,6-dichloroanilino)phenylacetamido]hexanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{8-[2-(2,6-dichloroanilino)phenylacetamido]octanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{12-[2-(2,6-dichloroanilino)phenylacetamido]dodecanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{3-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]propanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{4-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]butanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{5-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]valeroyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]hexanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{8-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl indolylacetamido]octanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{3-[α-methyl-4-(2-methylpropyl)benzeneacetamido]propanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{6-[α-methyl-4-(2-methylpropyl)benzeneacetamido]hexanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{3-[(S)-6-methoxy-α-methyl-2-naphthleneacetamido]propanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{4-[(S)-6-methoxy-α-methyl-2-naphthaleneacetamido]butanoyl}-sn-glycero-3-phosphocholine,
1-Stearoyl-2-{6-[(S)-6-methoxy-α-methyl-2-naphtaleneacetamido]hexanoyl}-sn-glycero-3-phosphocholine, and
1-Stearoyl-2-{4-[2-(6-methoxynaphthyl)acetamido]butanoyl}-sn-glycero-3-phosphocholine.

### Claim 17 (depends on 9)

The pharmaceutical composition according to claim 9, in the form of solutions, suspensions, capsules, tablets, aerosols, gels, ointments or suppositories.

### Claim 18 (depends on 9)

The pharmaceutical composition according to claim 9 for oral, ocular, nasal, parenteral, topical or rectal administration.

### Claim 19 (depends on 18)

The pharmaceutical composition according to claim 18 for oral administration.

### Claim 20 (depends on 18)

The pharmaceutical composition according to claim 18 for nasal administration.

### Claim 21 (depends on 9)

The pharmaceutical composition according to claim 9 for the treatment of inflammation.

### Claim 22 (depends on 9)

The pharmaceutical composition according to claim 9, for the treatment of a disease or disorder related to an inflammatory condition, wherein said disease or disorder related to an inflammatory condition, is selected from the group consisting of arthritis, rheumatoid arthritis, asthma, psoriasis, systemic lupus erythematosus, inflammatory bowel syndrome and the neurological diseases and disorders multiple sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, vascular dementia, epilepsy, migraines, stroke and trauma.

### Claim 23 (depends on 9)

A method for treatment of inflammation comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 9.

### Claim 24 (depends on 9)

The method for treatment of a disease or disorder related to an inflammatory condition comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 9 wherein said disease or disorder related to an inflammatory condition is selected from the group consisting of arthritis, rheumatoid arthritis, asthma, psoriasis, systemic lupus erythematosus, inflammatory bowel syndrome and the neurological diseases and disorders multiple sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, vascular dementia, epilepsy, migraines, stroke and trauma.

### Claim 25 (depends on 1)

A process for the synthesis of compounds of the general formula I as defined in claim 1, comprising:
(i) providing a molecule y—X—Z—COOH, wherein y is selected from H and OH, Z is a saturated hydrocarbon chain having from 2 to 15 carbon atoms, and X is selected from amino and thio groups;
(ii) replacing y with an appropriate blocking group, B, selected from the group consisting of benzyl chloromate, benzyloxycarbonate, diphenylcarbinol and trimethylacetamidocarbinol;
(iii) preparing an anhydride of the molecule B—X—Z—COOH by employing a reagent to remove one molecule of water from two protected bridging groups;
(iv) acylating a lyso-lecithin by the anhydride of step (iii) to yield 1-acyl-2-acyl(X—B)-sn-glycero-3 phospholipid by dissolving said anhydride and said lyso-lecithin in an organic solvent in the presence of a catalyst;
(v) removing the blocking group B from the functional group X; and
(vi) coupling a nonsteroidal anti-inflammatory drug D comprising indomethacin to the functional group X in an organic solvent in the presence of reagents that enable a condensation reaction wherein water molecules are removed, thus, generating a molecule of the general Formula I.

### Claim 26 (depends on 25)

The process according to claim 25 wherein the protected functional group X is —NH.

### Claim 27 (depends on 25)

The process according to claim 25 wherein the phospholipid of step (iv) is phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol or phosphatidylserine.
